FDA Budget, Funding Sources, and User Fees

The FDA operates through a hybrid funding model that draws on both congressional appropriations and industry-paid user fees — a structure that directly shapes the agency's regulatory capacity, review timelines, and enforcement resources. Understanding how the FDA is funded clarifies why certain review programs exist, how fee structures are negotiated, and what happens when funding levels fall short of operational demands. This page covers the agency's budget composition, the legal basis for user fees, the major fee programs by product category, and how appropriations decisions interact with fee-funded activities.

Definition and scope

The FDA's total annual budget combines two distinct funding streams: discretionary appropriations allocated by Congress through the annual appropriations process, and user fees collected from regulated industry under reauthorized statutory authority. For fiscal year 2023, the FDA's total program level exceeded $6.6 billion (FDA FY 2023 Budget Summary), with user fees accounting for roughly 45 percent of that total.

Appropriations fund core public health functions that cannot be assigned to a single industry applicant — including food safety inspections, tobacco regulation enforcement, surveillance programs, and activities where charging fees would create conflicts of interest. User fees fund defined review services provided to specific applicants, primarily in the drug, biologics, and medical device product areas.

The legal authority for user fee collection rests on product-specific statutes enacted by Congress, not on general administrative discretion. Each major fee program requires periodic reauthorization — typically on a five-year cycle — and the terms of that reauthorization are shaped by negotiated agreements between the FDA and affected industry groups. Without reauthorization, fee collection lapses and the agency must rely solely on appropriations, which historically has forced hiring freezes and extended review timelines.

For context on the broader institutional role these funding decisions support, see the FDA overview and the agency's mission and authority.

How it works

The FDA's user fee programs operate under a defined framework:

1. Statutory authorization: Congress enacts a user fee statute for a specific product category (e.g., prescription drugs, generic drugs, biosimilars, medical devices).
2. Negotiated agreement: FDA staff and industry representatives negotiate performance goals — primarily review timelines — that the agency commits to meet in exchange for fee revenue.
3. Congressional reauthorization: Congress reviews and reauthorizes the program, typically incorporating the negotiated agreement into the legislative record.
4. Annual fee-setting: FDA calculates the fee amounts needed to fund agreed activities and publishes rates in the Federal Register each fiscal year.
5. Collection and appropriation: Fees collected are appropriated back to the FDA through a separate appropriations line, meaning Congress still controls how collected fees are spent.

The four largest user fee programs are:

• Prescription Drug User Fee Act (PDUFA): Covers new drug applications and biologics license applications reviewed by the Center for Drug Evaluation and Research (CDER). PDUFA was first enacted in 1992 and has been reauthorized six times as of PDUFA VII, which took effect in FY 2023 (FDA PDUFA VII).
• Medical Device User Fee Amendments (MDUFA): Covers 510(k) submissions, premarket approval applications, and de novo requests reviewed by the Center for Devices and Radiological Health (CDRH). For a detailed look at device classification, see FDA Medical Device Classification.
• Generic Drug User Fee Amendments (GDUFA): Covers abbreviated new drug applications and the associated facility fees for generic drug manufacturers.
• Biosimilar User Fee Act (BsUFA): Covers biosimilar biological product development and application review.

A meaningful contrast exists between application fees and program fees. Application fees are one-time charges tied to a specific submission (e.g., filing a new drug application). Program fees — such as annual establishment fees and product fees under PDUFA — are assessed annually against all products and facilities in the relevant category, regardless of whether the sponsor has an active application under review. This distinction affects budgeting for both large manufacturers and smaller applicants who may face disproportionate program fee burdens.

Common scenarios

Reauthorization gaps: If Congress fails to reauthorize a user fee program before the existing authority expires, fee collection halts immediately. In 2022, a brief congressional delay in passing PDUFA VII created a temporary staffing uncertainty at CDER, illustrating the operational dependency on timely reauthorization.

Small business fee waivers and reductions: Certain fee programs include tiered relief mechanisms. Under PDUFA, first-time human drug application filers meeting small business criteria may qualify for a waiver of the application fee, which for FY 2023 was set at $3,242,026 per standard application (FDA PDUFA FY 2023 fee schedule). This is a statutory provision, not a discretionary grant.

Tobacco and food safety funding: Neither tobacco regulation under the Family Smoking Prevention and Tobacco Control Act nor food safety activities under the Food Safety Modernization Act relies primarily on user fees structured like PDUFA. Tobacco fees are assessed against manufacturers based on market share, while food safety activities depend heavily on appropriations, creating recurring tension when appropriations do not keep pace with FSMA implementation requirements.

Supplemental appropriations: During declared public health emergencies, Congress has provided supplemental appropriations outside the normal cycle to support activities such as Emergency Use Authorization reviews and vaccine regulation. These funds operate separately from the standing user fee programs.

Decision boundaries

The distinction between what user fees may fund and what must be funded through appropriations is not purely administrative — it reflects statutory constraints embedded in each fee authorization. FDA is prohibited from using PDUFA funds for activities unrelated to the review of human drug applications. Attempting to redirect user fee revenue to, for example, food inspection activities would constitute an unauthorized use of appropriated funds under the Antideficiency Act (31 U.S.C. § 1341).

A further boundary exists around independence in review decisions. Federal law and FDA policy explicitly state that user fee payments do not and cannot influence the scientific determination in a product review. This boundary is structural: fees fund reviewer salaries and infrastructure, not outcomes. The FDA inspection process and enforcement actions remain appropriations-funded activities specifically to preserve independence from any financial relationship with regulated entities.

When appropriations and user fees together prove insufficient — as demonstrated during extended continuing resolutions that freeze spending at prior-year levels — the FDA's published guidance on drug shortage management and good manufacturing practices can be affected by reduced inspection frequency, since those functions draw on constrained appropriations rather than fee revenue.